Angiogenesis and lymphangiogenesis and their role in non-Hodgkin's lymphomas;Angiogeneza i limfangiogeneza oraz ich znaczenie w nieziarniczych chłoniakach złośliwych

Acta Haematologica Polonica

Volumn 41, Issue 1, 2010, Pages 21-33

  Wosztyl, Anna ^a   Korycka Wołowiec, Anna ^b  

^a Swietokrzyskie Centrum Onkologii Poland   (Poland)

^b Z Kliniki Hematologii Uniw Medycznego I Wojewodzklego Szpitala Specjalistycznego im M Kopernika W ^*  (Poland)

Author keywords

Angiogenesis; Antiangiogenic therapy; Lymphangiogenesis; Non Hodgkin's lymphomas; Proangiogenic factors

Indexed keywords

ANGIOPOIETIN; BEVACIZUMAB; BORTEZOMIB; CYCLOPHOSPHAMIDE; CYTOKINE; DOXORUBICIN; GELATINASE A; GELATINASE B; INTERFERON; LENALIDOMIDE; N (2 AMINOPHENYL) 4 [4 (3 PYRIDINYL) 2 PYRIMIDINYLAMINOMETHYL]BENZAMIDE; PANOBINOSTAT; PREDNISONE; RITUXIMAB; SUNITINIB; TEMSIROLIMUS; THALIDOMIDE; THROMBOSPONDIN; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN B; VASCULOTROPIN C; VASCULOTROPIN D; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3; VINCRISTINE; VORINOSTAT;

ANGIOGENESIS; BLOOD VESSEL; CANCER INHIBITION; CANCER INVASION; CANCER THERAPY; ENDOTHELIUM CELL; FOLLICULAR LYMPHOMA; HISTOPATHOLOGY; HUMAN; LARGE CELL LYMPHOMA; LEUKEMOGENESIS; LYMPH VESSEL; LYMPHANGIOGENESIS; MANTLE CELL LYMPHOMA; NONHODGKIN LYMPHOMA; REVIEW; T CELL LYMPHOMA; VON HIPPEL LINDAU DISEASE;

EID: 77954111920     PISSN: 00015814     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (60)

1. Jorgensen JM, Sorensen F.B, Bendix K i wsp. Angiogenesis in non-Hodgkin's lymphoma: clinico-pathological correlations and prognostic significance in specific subtypes. Leuk Lymphoma 2007; 48: 584-595.
2. Fukushima N, Satoh T, Sano M, Tokunaga O. Angiogenesis and mast cells in non-Hodgkin's lymphoma: a strong correlation in angioimmunoblastic T-cell lymphoma. Leuk Lymphoma 2001; 42: 709-720. (Pubitemid 32782779)
3. Passam FH, Sfiridaki A, Pappa C i wsp. Angiogenesis-related growth factors and cytokines in the serum of patients with B-non-Hodgkin lymphoma; relation to clinical features and response to treatment. Int J Lab Hematol. 2008; 30: 17-25.
4. Younes A. Angiogenesis in lymphoma: a short review. Curr Mol Med 2005; 5: 609-613.
5. Tammela T, Enholm B, Alitalo K, Paavonen K. The biology of vascular endothelial growth factors. Cardiovasc Res. 2005; 65: 550-563
6. Wigle JT, Harvey N, Detmar M i wsp. An essential role for Prox 1 in the induction of lymphatic endothelial cell phenotype. EMBO J 2002; 21: 1505-1513.
7. Petrova TV, Makinen T, Makela TP i wsp. Lymphatic endothelial reprogramming of vascular endothelial cells by the Prox-1 homeobox transcription factor. EMBO J 2002; 21: 4593-4599.
8. Asahara T, Masuda H, Takahashi T i wsp. "Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularisation.". Circ Res 1999; 85: 221-228.
9. Sundar SS, Ganesan TS. Role of lymphangiogiogenesis in cancer. J Clin Oncol 2007; 25: 4298-4307
10. Carmeliet P. Angiogenesis in health and disease. Nat Med 2003; 9: 653-660.
11. Aiello LP, Avery RL, Arrig PG i wsp. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994; 331: 1480-1487.
12. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285: 1182-1186.
13. Dhakal HP, Bassarova A, Naume E i wsp. Breast carcinoma vascularity: a comparison of manual microvessel count and Chalkley count. Histol Histopathol 2009, 24: 1049-1059.
14. Hempel N, Ye H, Abessi B, Mian B, Melendez JA. Altered redox status accompaniers progression to metastatic human bladder cancer. Free Radic Biol Med. 2009; 46: 42-50.
15. Kluetz PG, Figg WD, Dahut WL. Angiogenesis inhibition in the treatment of prostate cancer. Expert Oppin Pharmacother 2010; 11: 233-247.
16. Aguayo A A, Kantarjian H, Manshouri T i wsp. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood 2000; 96: 2240-2245.
17. Klagsbrun M, Moses MA. Molecular angiogenesis. Chem Biol. 1999; 6: 217-224.
18. Ganjoo K. Antiangiogenesis: a new approach to the treatment of lymphoma. Leuk Lymphoma 2007; 48: 454-455.
19. Gratzinger D, Zhao S, Marinelli RJ i wsp. Microvessel density and expression of vascular endothelial growth factor and its receptors in diffuse large-B-cell lymphoma subtypes. Am J Pathol 2007; 170: 1362-1369.
20. Arias V, Soares FA, Vascular density (tumor angiogenesis) in non-Hodgkin's lymphoma and florid follicular hyperplasia: a morphometric study. Leuk Lymphoma 2000; 40: 157-166.
21. Hansen S, Grabau DA, Sorensen FB, Bak M, Vach W, Rose C. The prognostic value of angiogenesis by Chalkley counting in a confirmatory study design on 836 breast cancer patients. Clin Cancer Res. 2000; 6: 139-146. (Pubitemid 30064986)
22. Fox SB, Leek RD, Weekes MP, Whitehouse RM, Garter KC, Harris AL. Quantitation and prognostic value of breast cancer angiogenesis: comparison of microvessel density, Chalkley count, and computer image analysis. J Pathol 1995; 177: 275-283.
23. Banerji S, Ni J, Wang SX i wsp. LIVE-1, a new homologue of CD44 glycoprotein, is a lymph-specific receptor for hyaluronan. J Cell Biol 1999; 144: 789-801.
24. Hirakawa S, Hong Y, Harvey N i wsp. Identification of vascular lineage-specific genes by transcriptional profiling of isolated blood vascular and lymphatic endothelial cells A J Pathol 2003; 162: 575-586.
25. Kahn HJ, Marks A. A new monoclonal antibody, D2-40, for detection of lymphatic invasion in primary tumors. Lab Invest 2002; 82: 1255-1257. (Pubitemid 35014860)
26. Klagsbrun M, Takashima S, Mamluk R. The role of neuropilin in vascular and tumor biology. Adv Exp Med Biol 2002; 515: 33-48. (Pubitemid 36324180)
27. Igreja C, Courinha C, Cachaco AS i wsp. Characterization and clinical relevance of circulating and biopsy-derived endothelial progenitor cells in lymphoma patients. Haematologica.2007; 92: 469-477.
28. Hazar B, Polat G, Seyrek E, Bagdatoglglu O, Kanik A, Tiftic N. Prognostic value of matrix metalloproteinases (MMP-2 and MMP-9) in Hodgkin's and non-Hodgkin's lymphoma. Int J Clin Pract 2004; 58: 139-143.
29. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9: 669-679.
30. Roy H, Bhardwaj S, Yla-Herttuala S. Biology of vascular endothelial growth factors. FEBS Letters 2006; 580: 2879-2887.
31. Maglione D, Guerriero V, Viglietto G, Delli-Bovi P, Persico MG. Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor. Proc Natl Acad Sci USA 1991, 88, 9267-9271. (Pubitemid 21915612)
32. Siegfried G, Basak A, Cromlish JA i wsp. The secretory proprotein convertases furin, PC5, and PC7 activate VEGF-C to induce tumorgenesis. J Clin Invest 2003; 111: 1723-1732.
33. Cao R, Bjorndahl MA, Gallego MI i wsp. Hepatocyte growth factor is a lymphangiogenic factor with an indirect mechanism of action. Blood 2006; 107: 3531-3536.
34. Salven P, Teerenhovi L, Joensuu H. A high pretreatment serum basic fibroblast growth factor concentration i an independent predictor of poor prognosis in non-Hodgkin's lymphoma. Blood 1999; 94: 3334-3339.
35. Salven P, Orpana A, Teerenhovi L, Joensuu H. Simultaneous elevation in the sera concentrations of angiogenic growth factors VEGF and bFGF is independent predictor of poor prognosis in non-Hodgkin's lymphoma: a single institution study of 200 patients. Blood 2000; 96: 3712-3718.
36. Wierzbowska A. Ocena angiogenezy i jej znaczenie prognostyczne w ostrej białaczce szpikowej. Praca habilitacyjna, Łódź, 2008.
37. Moehler TM, Hillengass J, Goldschmidt H, Ho AD. Antiangiogenic Therapy in Hematologic Malignancies. Curr Pharmaceutical Design 2004; 10: 1221-1234.
38. Mukhopadhyay D, Tsiokas L, Sukhatme VP. Wilde-type p53 and v-Src exert opposing influence of human vascular endothelial growth factor gen expression. Cancer Res 1995; 55: 6161-6165.
39. Pagnano KB, Vassallo J, Lorand-Metze I, Costa FF, Saad ST. p53, Mdm2 and c-Myc overexpression is associated with a poor prognosis in aggressive non-Hodgkin's lymphomas. Am J Hematol 2001; 67: 84-92.
40. Tzankov A, Heiss S, Ebner S. i wsp. Angiogenesis in nodal B-cell lymphomas: a high throughput study. J Clin Pathol 2007; 60: 476-482.
41. Aref S, Mabed M, Zalata K, Sakrana M, El Askalany H. The interplay between c-myc oncogen expression and circulating vascular endothelial growth factor (sVEGF), its antagonist receptor, soluble Flt-1 in Diffuse Large B Cell Lymphoma (DLBCL): Relationship to patient outcome. Leuk Lymphoma 2004; 45: 499-506. (Pubitemid 38196032)
42. Kawasaki C, Ohshim K, Suzumiya J i wsp. Rearrangements of bcl-1, bcl-2, bcl-6 and c-Myc in diffuse large B-cell lymphomas. Leuk Lymphoma 2001; 42: 1096-1099.
43. Witzenbichler B, Maisonpierre PC, Jones P, Yancopoulos GD, Isner JM. Chemotactic properties of angiopoietin -1 and -2, ligands for the endothelial-specific receptor tyrosine kinase Tie2. J Biol Chem 1998; 273: 18514-18521.
44. Morisada T, Oike Y, Yamada Y i wsp. Angiopoietin-1 promotes LYVE-1 positive lymphatic vessel formation. Blood 2005; 105: 4649-4656.
45. Lobov IB, Brooks PC, Lang RA. Angiopoietin-2 displays VEGF -dependent modulation of capillary structure and endothelial cell survival in vivo. Proc Natl Acad Sci USA 2002; 99: 11205-11210.
46. Fingleton B. Matrix metalloproteinases (MMPs): roles in cancer and metastasis. Front Biosci 2006; 11: 479-491 (Pubitemid 43258157)
47. Miyamoto S, Teramoto H, Gutkind JS i wsp. Integrin can collaborate with growth factors for fosphorylation of receptor tyrosine kinases and MAP kinase activation: roles of integrin aggregation and occupancy of receptors. J Cell Biol 1996; 135: 1633-1642.
48. Etto LY, Regis Silva MR, Dalboni MA, Alves AC, Colleoni GWB. Proangiogenic cytokines produced by non-Hodgkin lymphoma tumor cells induce angiogenesis in infiltrated bone marrow samples. Leuk Lymphoma 2009; 50: 1381-1383
49. Mazur G, Wróbel T, Dziȩgiel P, Jeleń M, Kuliczkowski K, Zabel M. Angiogenesis measure by expression of CD34 antigen in lymph nodes of patients with non-Hodgkin's lymphoma. Folia Histochem Cytobiol 2004; 42: 241-243.
50. Foss H.D, Araujo I, Demel G, Klotzbach H, Hummel M, Stein H. Expression of vascular endothelial growth factor in lymphomas and Castleman's disease. J Pathol 1997; 183: 44-50.
51. Wróbel T, Mazur G, Usnarska-Zubkiewicz L, Kuliczkowski K. Vascular endothelial growfh factor (VEGF) serum concentration in non-Hodgkins lymphoma patients. Pol Arch Med Wewn 2004; 112: 919-923.
52. Ruan J, Leonard JP. Targeting angiogenesis: a novel, rational therapeutic approach for non-Hodgkin lymphoma. Leuk Lymphoma 2009; 50: 679-681.
53. Stopeck AT, Unger JM, Rimsza LM i wsp. A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: Southwest Oncology Group Study S0108. Leuk Lymphoma 2009; 50: 728-735.
54. Ruan J, Hajjar K, Rafii S, Leonard JP. Angiogenesis and antiangiogenic therapy in non-Hodgkin's lymphoma. Annals Oncol. 2009; 20: 413-424.
55. Ganjoo KN, An CS, Robertson MJ i wsp. Rituximab, bevacizumab and CHOP (RA-CHOP) in untreated diffuse large B-cell lymphoma: safety, biomarker and pharmacokinetic analysis. Leuk Lymphoma 2006; 47: 998-1005.
56. Levine AM Tulpule A, Quinn D i wsp. Phase I study of antisense oligonucleotide against vascular endothelial growth factor: decrease in plasma vascular endothelial growth factor with potential clinical efficacy. J Clin Oncol 2006; 24: 1712-1719.
57. Pro B, Younes A, Albitar M, Dang NH i wsp. Thalidomide for patients with recurrent lymphoma. Cancer 2004; 15:1186-1189.
58. Witzig TE, Vose JM, Pietronigro D i wsp. Prelominary results from a phase II study of lenalidomide oral monotherapy in relapsed/refractory indolent non-Hodgkin lymphoma. J Clin Oncol 2007, 25 (supl) :8066.
59. Buckstein R, Meyer RM, Seymour L i wsp. Phase II testing of sunitinib: the National Cancer Institute of Canada Clinical Trials Group IND Program Trials IND 182-185. Curr Oncol 2007; 14: 154-161.
60. O'Connor AO, Wright J, Moskowitz C i wsp. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 2005; 23: 676-684.